Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22185877 | 0.89 | DPP4 (0.39) | EIF4A3ALOX15ALOX12FABP3FABP4 | |
| SCHEMBL14404558 | 0.87 | DPP4 (0.38) | EIF4A3ALOX15ALOX12FABP3FABP4 | |
| SCHEMBL12896237 | 0.87 | DPP4 (0.38) | EIF4A3ALOX15ALOX12FABP3FABP4 | |
| SCHEMBL27308803 | 0.83 | EIF4A3 (0.36) | EIF4A3ALOX15ALOX12 | |
| SCHEMBL10552802 | 0.82 | EIF4A3 (0.35) | EIF4A3PDE2A | |
| SCHEMBL22251582 | 0.82 | ALOX15 (0.46) | ALOX15ALOX12 | |
| SCHEMBL13413598 | 0.82 | GRIN2D (0.39) | EIF4A3ALOX15ALOX12PDE2A | |
| SCHEMBL9418090 | 0.82 | TRPV4 (0.31) | — | |
| SCHEMBL6269855 | 0.81 | ALOX15 (0.37) | ALOX15ALOX12FABP3FABP4FABP5 | |
| SCHEMBL24868584 | 0.81 | GABRA1 (0.33) | EIF4A3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083269-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023279986-A1 | SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF | 贝达药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20220175754-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | PML, TARDBP, PRNP | EIF4A3 1324/4885ALOX15 4227/4885ALOX12 4084/4885 |
| US-20220175754-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | PML, TARDBP, PRNP | EIF4A3 1324/4885ALOX15 4227/4885ALOX12 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.